Maryland State Retirement & Pension System Cuts Stock Holdings in ICU Medical, Inc. $ICUI

Maryland State Retirement & Pension System cut its position in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 50.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,549 shares of the medical instruments supplier’s stock after selling 3,684 shares during the period. Maryland State Retirement & Pension System’s holdings in ICU Medical were worth $426,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ICUI. River Road Asset Management LLC raised its position in shares of ICU Medical by 207.0% in the second quarter. River Road Asset Management LLC now owns 651,492 shares of the medical instruments supplier’s stock worth $83,658,000 after acquiring an additional 439,263 shares during the period. Norges Bank purchased a new position in shares of ICU Medical in the 2nd quarter valued at about $36,633,000. William Blair Investment Management LLC acquired a new position in ICU Medical in the 2nd quarter worth about $27,928,000. The Manufacturers Life Insurance Company boosted its position in ICU Medical by 75.1% during the second quarter. The Manufacturers Life Insurance Company now owns 228,909 shares of the medical instruments supplier’s stock worth $30,250,000 after purchasing an additional 98,147 shares in the last quarter. Finally, Quantinno Capital Management LP boosted its position in ICU Medical by 129.9% during the second quarter. Quantinno Capital Management LP now owns 135,142 shares of the medical instruments supplier’s stock worth $17,859,000 after purchasing an additional 76,352 shares in the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

Insider Transactions at ICU Medical

In other ICU Medical news, Director Elisha W. Finney sold 1,285 shares of the firm’s stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $140.42, for a total value of $180,439.70. Following the transaction, the director directly owned 3,995 shares of the company’s stock, valued at $560,977.90. This trade represents a 24.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Virginia Ruth Sanzone sold 930 shares of the company’s stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $142.34, for a total value of $132,376.20. Following the completion of the sale, the vice president owned 5,456 shares of the company’s stock, valued at $776,607.04. This trade represents a 14.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 1.50% of the stock is currently owned by corporate insiders.

ICU Medical Stock Down 3.7%

NASDAQ ICUI opened at $152.67 on Friday. The business has a fifty day moving average price of $146.95 and a 200 day moving average price of $132.89. ICU Medical, Inc. has a one year low of $107.00 and a one year high of $175.51. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.19 and a current ratio of 2.45. The company has a market cap of $3.77 billion, a P/E ratio of -492.47 and a beta of 0.80.

ICU Medical (NASDAQ:ICUI) last announced its earnings results on Thursday, November 6th. The medical instruments supplier reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.43 by $0.60. The company had revenue of $533.30 million for the quarter, compared to analysts’ expectations of $511.46 million. ICU Medical had a negative net margin of 0.32% and a positive return on equity of 7.71%. The firm’s quarterly revenue was down 8.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.59 EPS. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. Research analysts anticipate that ICU Medical, Inc. will post 4.11 EPS for the current fiscal year.

Analysts Set New Price Targets

ICUI has been the subject of a number of recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of ICU Medical in a research report on Thursday. Piper Sandler lifted their price target on shares of ICU Medical from $153.00 to $172.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Wall Street Zen raised shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Monday, January 19th. Finally, KeyCorp increased their price objective on shares of ICU Medical from $173.00 to $175.00 and gave the company an “overweight” rating in a report on Friday, November 7th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $175.67.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.